Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3050002 in Psoriatic Arthritis
NCT02671188Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriatic arthritis (PsA) comparing GSK3050002 with Placebo (2 arms). Primary endpoints: Number of subjects with Adverse Events, Number of subjects with Serious Adverse Events and 3 more. Planned start Jun 2018; status: withdrawn.
02
Drugs
gsk3050002
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02671188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671188.